Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl

@article{Li2005PreclinicalPO,
  title={Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl},
  author={Mao Li and Hui Wang and Donald L. Hill and Sherman F. Stinson and Karen Veley and Irma M. Grossi and James O. Peggins and Joseph M. Covey and Ruiwen Zhang},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2005},
  volume={57},
  pages={607-614}
}
  • Mao Li, Hui Wang, +6 authors Ruiwen Zhang
  • Published in
    Cancer Chemotherapy and…
    2005
  • Medicine
  • Purpose: To define several pharmacological properties for the potential anticancer agent, adaphostin, in order to determine whether the compound is appropriate for clinical evaluation as an anticancer agent. Methods: The analytical procedure involved high-performance liquid chromatography and utilized an analytical J’Sphere ODS H-80 column. Results: The stability of adaphostin at two different concentrations was determined at temperatures of 37°C, 4°C, and -80°C, in the plasma of mice, rats… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 12 REFERENCES

    Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro.

    VIEW 2 EXCERPTS

    Effect of aspirin on pharmacokinetics of antisense oligonucleotides in rats

    • S Agrawal, X Zhang, +4 authors R Zhang
    • J Drug Target
    • 1998
    VIEW 1 EXCERPT

    Endothelial receptor tyrosine kinases involved in angiogenesis

    VIEW 1 EXCERPT